Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Genomic profiling as an option for ovarian cancer diagnostics.

Expert review of molecular diagnostics·2026
Same author

Fertility-sparing treatment in stage IA grade 2 endometrioid endometrial cancer: Outcomes of a standardized approach.

Gynecologic oncology·2026
Same author

Fluoropyrimidine Cardiotoxicity: Role of Uridine Triacetate and Pharmacogenomic Insights from a Case of 5-FU-Induced Cardiogenic Shock.

Journal of cardiovascular pharmacology·2026
Same author

p16(INK4a) immunohistochemical expression is a strong predictor of treatment response and survival in patients with locally advanced squamous cell vulvar cancer undergoing upfront chemoradiotherapy.

Journal of gynecologic oncology·2026
Same author

LANTERN 2: Association Between Gene Molecular Profile and STAS in Lung Adenocarcinoma: A Comparative Analysis in a Prospective Real-World Population.

Genes·2026

Related Experiment Video

Updated: Jun 4, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single-center

Camilla Nero1,2, Rita Trozzi1,2, Federica Persiani2,3

  • 1Unit of Oncological Gynecology, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Cancer
|January 26, 2025
PubMed
Summary

Endometrial cancer (EC) patients with DNA polymerase epsilon (POLE) hotspot mutations (POLEmut) show similar genomic profiles regardless of risk factors. Further research is needed for non-hotspot POLE mutations in EC.

Keywords:
DNA polymerase epsilon (POLE)POLE hotspotsPOLE multiclassifieradjuvant therapycomprehensive genomic profilingendometrial cancermolecular classification

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.3K

Related Experiment Videos

Last Updated: Jun 4, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.3K

Area of Science:

  • Genomic analysis of cancer-related genes.
  • Oncology and molecular diagnostics.

Background:

  • Eleven DNA polymerase epsilon (POLE) pathogenic variants are recognized as "hotspot" mutations.
  • Patients with endometrial cancer (EC) and POLE hotspot mutations (POLEmut) exhibit superior survival outcomes.
  • Current guidelines recommend de-escalating adjuvant treatment for early-stage POLEmut EC, but safety in high-risk cases requires further study.

Purpose of the Study:

  • To compare the genomic landscape of POLEmut EC with EC harboring non-hotspot POLE mutations.
  • To examine genomic characteristics in POLEmut EC with unfavorable clinical and histopathological features.
  • To investigate the genomic features of POLE variants not classified as hotspots.

Main Methods:

  • Comprehensive genomic analysis of 596 EC patients.
  • Comparison of genomic profiles between POLEmut EC and EC with non-hotspot POLE mutations.
  • Examination of genomic characteristics based on clinical classifiers and histopathological features.

Main Results:

  • No significant genomic differences were found in POLEmut EC when comparing multiple classifiers or unfavorable clinical features.
  • Tumor mutational burden differed between groups based on classifiers and clinical features.
  • Specific POLE mutations, including non-hotspot variants, demonstrated genomic features comparable to POLEmut.

Conclusions:

  • POLEmut EC patients do not show significant genomic differences irrespective of classifier status or high-risk clinical features.
  • The clinical significance of non-hotspot POLE mutations with POLEmut-like genomic features requires further investigation through prognostic data.